These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 38236031)

  • 1. Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by
    Farrington N; Dubey V; Johnson A; Horner I; Stevenson A; Unsworth J; Jimenez-Valverde A; Schwartz J; Das S; Hope W; Darlow CA
    mBio; 2024 Feb; 15(2):e0316523. PubMed ID: 38236031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model.
    Avent ML; McCarthy KL; Sime FB; Naicker S; Heffernan AJ; Wallis SC; Paterson DL; Roberts JA
    Microbiol Spectr; 2022 Jun; 10(3):e0052522. PubMed ID: 35442072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP).
    Johnson MG; Bruno C; Castanheira M; Yu B; Huntington JA; Carmelitano P; Rhee EG; De Anda C; Motyl M
    Int J Antimicrob Agents; 2021 Mar; 57(3):106278. PubMed ID: 33434676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of a rabbit model of
    Gras E; Vu TTT; Nguyen NTQ; Tran VG; Mao Y; Tran ND; Mai NH; Dong OX; Jung DH; Iorio NLPP; Povoa HCC; Pinheiro MG; Aguiar-Alves F; Weiss WJ; Zheng B; Cheng LI; Stover CK; Sellman BR; DiGiandomenico A; Gibault L; Valour F; Diep BA
    Front Cell Infect Microbiol; 2023; 13():1297281. PubMed ID: 38149013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial resistance profiles and associated factors of Acinetobacter and Pseudomonas aeruginosa nosocomial infection among patients admitted at Dessie comprehensive specialized Hospital, North-East Ethiopia. A cross-sectional study.
    Mekonnen H; Seid A; Molla Fenta G; Gebrecherkos T
    PLoS One; 2021; 16(11):e0257272. PubMed ID: 34780494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection.
    Wang Y; Li C; Wang J; Bai N; Zhang H; Chi Y; Cai Y
    Microbiol Spectr; 2022 Oct; 10(5):e0146822. PubMed ID: 36102678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nebulized Amikacin and Fosfomycin for Severe Pseudomonas aeruginosa Pneumonia: An Experimental Study.
    Li Bassi G; Motos A; Fernandez-Barat L; Aguilera Xiol E; Chiurazzi C; Senussi T; Saco MA; Fuster C; Carbonara M; Bobi J; Amaro R; De Rosa F; Comaru T; Yang H; Ranzani OT; Marti JD; Rinaudo M; Comino Trinidad O; Rigol M; Bringué J; Ramirez J; Nicolau DP; Pelosi P; Antonelli M; Blasi F; Artigas A; Montgomery AB; Torres A
    Crit Care Med; 2019 Jun; 47(6):e470-e477. PubMed ID: 30882478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chinese expert consensus on the management of lower respiratory tract infections of
    Pulmonary Infection Assembly of Chinese Thoracic Society
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Aug; 45(8):739-752. PubMed ID: 35927044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia.
    Kim A; Kuti JL; Nicolau DP
    Clin Ther; 2009 Nov; 31(11):2765-78. PubMed ID: 20110018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia.
    Motos A; Yang H; Li Bassi G; Yang M; Meli A; Battaglini D; Cabrera R; Bobi J; Pagliara F; Frigola G; Camprubí-Rimblas M; Fernández-Barat L; Rigol M; Ferrer-Segarra A; Kiarostami K; Martinez D; Nicolau DP; Artigas A; Pelosi P; Vila J; Torres A
    Crit Care; 2023 Feb; 27(1):60. PubMed ID: 36788582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones.
    Montero MM; Domene Ochoa S; López-Causapé C; VanScoy B; Luque S; Sorlí L; Campillo N; Padilla E; Prim N; Segura C; Pomar V; Rivera A; Grau S; Ambrose PG; Oliver A; Horcajada JP
    J Glob Antimicrob Resist; 2019 Sep; 18():37-44. PubMed ID: 31154007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.
    Drusano GL; Neely MN; Yamada WM; Duncanson B; Brown D; Maynard M; Vicchiarelli M; Louie A
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic Evaluation of Plasma and Epithelial Lining Fluid Exposures of Amikacin against Pseudomonas aeruginosa in a Dynamic
    Heffernan AJ; Sime FB; Sarovich DS; Neely M; Guerra-Valero Y; Naicker S; Cottrell K; Harris P; Andrews KT; Ellwood D; Wallis SC; Lipman J; Grimwood K; Roberts JA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32660986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.